## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.2% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($819.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: Business Wire | 20251201T160626 | Bullish | Relevance: 99%
- McKesson Corporation announced the publication of its first Advancing Community Oncology Report, detailing trends and opportunities in community-based oncology. The report highlights strategies for biopharma and community practices to accelerate precision medicine, expand clinical trial access, and prepare for technology-driven care, based on insights from over 200 surveyed oncologists and staff, and industry experts. Key findings emphasize the need for collaboration to address challenges like keeping pace with innovations and accessing clinical trials, ultimately aiming to improve patient outcomes in community settings.

**2. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: 01net | 20251201T160617 | Bullish | Relevance: 97%
- McKesson Corporation has released its first-ever Advancing Community Oncology Report, highlighting trends and opportunities in community-based oncology. The report, based on surveys and conference insights, identifies key areas for biopharma and community practices to collaborate, including accelerating precision medicine, expanding clinical trial access, and preparing for technology-driven care. The goal is to strengthen the community oncology ecosystem and improve patient access to innovative therapies.

**3. Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion?**
- Source: Simply Wall Street | 20251201T045231 | Neutral | Relevance: 61%
- Henry Schein's stock recently rallied 18%, sparking debate on its future growth and risk. The company shows a strong valuation score of 5 out of 6 according to Simply Wall St's valuation checks, and a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 57.2%. Its Price-to-Earnings (PE) ratio is currently 22.45x, suggesting it is about fairly valued when compared to its tailored "Fair Ratio" of 24.99x.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.1B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 19.6 |
| Current P/E | 22.2 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.4% to -3.2% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Underperforming sector by 4.6pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.58), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.21% (CS: 12) | Weak |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | -1.58 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.192x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $856.89
- **Stop Loss:** $819.85 (4.3% risk)
- **Target:** $893.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $17,137.80
- **Portfolio %:** 17.14%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*